Trial of Curcumin in Advanced Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Pancreatic NeoplasmsAdenocarcinoma
Interventions
DRUG

Curcumin

Starting dose 8 gm orally per day for 8 weeks. If patient experiences grade III toxicity, dose held and restarted with a 50% dose reduction after resolution of toxicity to \</= Grade I. Patients with grade IV toxicity will discontinue treatments. Patients with \</= grade I toxicity may have a 25% dose increase at each four-week period. Patients will continue on treatment until disease progresses, unless Grade III toxicity supervenes.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Sabinsa Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00094445 - Trial of Curcumin in Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter